In mammals, highly lipophilic small molecule chemical agents can accumulate as inclusions within resident tissue macrophages. In this context, we characterized the biodistribution, chemical composition, and structure of crystal-like drug inclusions (CLDIs) formed by clofazimine (CFZ), a weakly basic lipophilic drug. With prolonged oral dosing, CFZ exhibited a significant partitioning with respect to serum and fat due to massive bioaccumulation and crystallization in the liver and spleen. The NMR, Raman, and powder X-ray diffraction (p-XRD) spectra of CLDIs isolated from the spleens of CFZ-treated mice matched the spectra of pure, CFZ hydrochloride crystals (CFZ-HCl). Elemental analysis revealed a 237-fold increase in chlorine content in CLDIs compared to untreated tissue samples and a 5-fold increase in chlorine content compared to CFZ-HCl, suggesting that the formation of CLDIs occurs through a chloride mediated crystallization mechanism. Single crystal analysis revealed that CFZ-HCl crystals had a densely packed orthorhombic lattice configuration. In vitro, CFZ-HCl formed at a pH of 4-5 only if chloride ions were present at sufficiently high concentrations (>50:1 Cl(-)/CFZ), indicating that intracellular chloride transport mechanisms play a key role in the formation of CLDIs. While microscopy and pharmacokinetic analyses clearly revealed crystallization and intracellular accumulation of the drug in vivo, the chemical and structural characterization of CLDIs implicates a concentrative, chloride transport mechanism, paralleling and thermodynamically stabilizing the massive bioaccumulation of a weakly basic drug.
In mammals, highly lipophilin class="Chemical">c small molecule chemical agents can accumulate as inclusions within resident tissue macrophages. In this context, we characterized the biodistribution, chemical composition, and structure of crystal-like drug inclusions (CLDIs) formed by clofazimine (CFZ), a weakly basic lipophilic drug. With prolonged oral dosing, CFZ exhibited a significant partitioning with respect to serum and fat due to massive bioaccumulation and crystallization in the liver and spleen. The NMR, Raman, and powder X-ray diffraction (p-XRD) spectra of CLDIs isolated from the spleens of CFZ-treated mice matched the spectra of pure, CFZ hydrochloridecrystals (CFZ-HCl). Elemental analysis revealed a 237-fold increase in chlorinecontent in CLDIscompared to untreated tissue samples and a 5-fold increase in chlorinecontent compared to CFZ-HCl, suggesting that the formation of CLDIs occurs through a chloride mediated crystallization mechanism. Single crystal analysis revealed that CFZ-HClcrystals had a densely packed orthorhombic lattice configuration. In vitro, CFZ-HCl formed at a pH of 4-5 only if chloride ions were present at sufficiently high concentrations (>50:1 Cl(-)/CFZ), indicating that intracellular chloride transport mechanisms play a key role in the formation of CLDIs. While microscopy and pharmacokinetic analyses clearly revealed crystallization and intracellular accumulation of the drug in vivo, the chemical and structural characterization of CLDIs implicates a concentrative, chloride transport mechanism, paralleling and thermodynamically stabilizing the massive bioaccumulation of a weakly basic drug.
Authors: Moloko C Cholo; Helen C Steel; P B Fourie; Willem A Germishuizen; Ronald Anderson Journal: J Antimicrob Chemother Date: 2011-10-20 Impact factor: 5.790
Authors: Lele Jiang; Kanin Salao; Hui Li; Joanna M Rybicka; Robin M Yates; Xu Wei Luo; Xin Xin Shi; Tamara Kuffner; Vicky Wang-Wei Tsai; Yasmin Husaini; Liyun Wu; David A Brown; Thomas Grewal; Louise J Brown; Paul M G Curmi; Samuel N Breit Journal: J Cell Sci Date: 2012-09-06 Impact factor: 5.285
Authors: Gi S Yoon; Sudha Sud; Rahul K Keswani; Jason Baik; Theodore J Standiford; Kathleen A Stringer; Gus R Rosania Journal: Mol Pharm Date: 2015-06-05 Impact factor: 4.939
Authors: Phillip Rzeczycki; Gi Sang Yoon; Rahul K Keswani; Sudha Sud; Jason Baik; Mikhail D Murashov; Ingrid L Bergin; Kathleen A Stringer; Gus R Rosania Journal: Pharm Res Date: 2018-11-07 Impact factor: 4.200
Authors: Elizabeth M Horstman; Rahul K Keswani; Benjamin A Frey; Phillip M Rzeczycki; Vernon LaLone; Jeffery A Bertke; Paul J A Kenis; Gus R Rosania Journal: Angew Chem Int Ed Engl Date: 2017-01-12 Impact factor: 15.336
Authors: Phillip Rzeczycki; Tehetina Woldemichael; Andrew Willmer; Mikhail D Murashov; Jason Baik; Rahul Keswani; Gi Sang Yoon; Kathleen A Stringer; Nair Rodriguez-Hornedo; Gus R Rosania Journal: Pharm Res Date: 2018-11-12 Impact factor: 4.200
Authors: Mikhail D Murashov; Vernon LaLone; Phillip M Rzeczycki; Rahul K Keswani; Gi S Yoon; Sudha Sud; Walajapet Rajeswaran; Scott Larsen; Kathleen A Stringer; Gus R Rosania Journal: J Invest Dermatol Date: 2017-10-16 Impact factor: 8.551
Authors: Gi S Yoon; Rahul K Keswani; Sudha Sud; Phillip M Rzeczycki; Mikhail D Murashov; Tony A Koehn; Theodore J Standiford; Kathleen A Stringer; Gus R Rosania Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191
Authors: Tehetina Woldemichael; Rahul K Keswani; Phillip M Rzeczycki; Mikhail D Murashov; Vernon LaLone; Brian Gregorka; Joel A Swanson; Kathleen A Stringer; Gus R Rosania Journal: Sci Rep Date: 2018-02-13 Impact factor: 4.379